1. 2250 Phase II trial of neoadjuvant gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy in resectable pancreatic adenocarcinoma. A GEMCAD 10–03 trial. (September 2015) Authors: Laquente, B.; Conill, C.; Fabregat, J.; Cambray, M.; Ayuso, J.R.; Valls, C.; Bombí, J.A.; Serrano, T.; Ferrández, A.; Povés, I.; Sabater, L.; Montagut, C.; Roselló, S.; Martín-Richard, M.; Díaz-Beveridge, R.; Rodriguez, J.; Gallego, R.; García-Alb éniz, X.; Fernández-Cruz, L.; Maurel, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S416 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Measuring biological responses at different levels of organisation to assess the effects of diffuse contamination derived from harbour and industrial activities in estuarine areas. Issue 1 (15th February 2016) Authors: de los Ríos, A.; Pérez, L.; Echavarri-Erasun, B.; Serrano, T.; Barbero, M.C.; Ortiz-Zarragoitia, M.; Orbea, A.; Juanes, J.A.; Cajaraville, M.P. Journal: Marine pollution bulletin Issue: Volume 103:Issue 1/2(2016:Feb.) Page Start: 301 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗